Facebook  |  Twitter  |  Google Plus  |  LinkedIn  |  Print

Australian Center Readies Brain Research Program for Addition of Elekta MEG System


4/26/2011 2:55 PM
Certain brain processes happen in the blink of an eye— and even faster—which has made pinpointing these events virtually impossible. The advent of magnetoencephalography (MEG) changed all that, enabling researchers to capture brain electrical activity measured in milliseconds, and offering the potential to reveal the nature of innumerable brain disorders and diseases. Swinburne University of Technology is set to join the global MEG community with the acquisition of Elekta Neuromag® TRIUX, Elekta’s latest generation MEG system.

“With MEG, you can localize and map where brain activity is happening and you can do that in real-time—from moment to moment—with millisecond resolution,” said Professor Michael Kyrios, director of Swinburne’s Brain and Psychological Sciences Research Centre. “This degree of ‘temporal resolution’ is unavailable in any other form of imaging, such as MRI, which provides great images but not particularly great temporal resolution. MEG is relatively new technology; it offers new possibilities and we want to be part of that.”

Swinburne’s Elekta Neuromag TRIUX system, scheduled to become operational in mid-2011, will be a part of the University’s Brain and Psychological Sciences Research Centre and will be sited in the new Advanced Technology Center (ATC). The ATC houses an array of brain research technology, such as a 3.0T MRI, EEG, and transcranial magnetic stimulation (TMS). Additional ATC facilities include clinical trial, psychopathology, and baby labs, as well as a center to disseminate evidence-based psychological treatments via the Internet.

Kyrios is overseeing the recruitment of several research staff who can use MEG’s unique capabilities in many areas. Broad categories include cognitive and visual processes, neurological diseases/disorders, and mental health disorders. Swinburne researchers will use their Elekta Neuromag TRIUX not only to explore the nature of diseases and disorders, but also to assess the impact of different treatments.

 

Related Company

Related News